This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v2.0 and MutSigCV v0.9 merged result was used to generate the results found in this report.
-
Working with individual set: STAD-TP
-
Number of patients in set: 221
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:STAD-TP.final_analysis_set.maf
-
Significantly mutated genes (q ≤ 0.1): 22
-
Mutations seen in COSMIC: 504
-
Significantly mutated genes in COSMIC territory: 30
-
Significantly mutated genesets: 18
-
Read 221 MAFs of type "Broad"
-
Total number of mutations in input MAFs: 112521
-
After removing 38 mutations outside chr1-24: 112483
-
After removing 2156 noncoding mutations: 110327
-
Number of mutations before filtering: 110327
-
After removing 1499 mutations outside gene set: 108828
-
After removing 117 mutations outside category set: 108711
-
After removing 3 "impossible" mutations in
-
gene-patient-category bins of zero coverage: 107092
Table 1. Get Full Table Table representing breakdown of mutations by type.
| type | count |
|---|---|
| Frame_Shift_Del | 2300 |
| Frame_Shift_Ins | 513 |
| In_Frame_Del | 204 |
| In_Frame_Ins | 10 |
| Missense_Mutation | 70797 |
| Nonsense_Mutation | 3553 |
| Nonstop_Mutation | 72 |
| Silent | 29494 |
| Splice_Site | 1570 |
| Translation_Start_Site | 198 |
| Total | 108711 |
Table 2. Get Full Table A breakdown of mutation rates per category discovered for this individual set.
| category | n | N | rate | rate_per_mb | relative_rate | exp_ns_s_ratio |
|---|---|---|---|---|---|---|
| *CpG->T | 25194 | 355853720 | 0.000071 | 71 | 5.8 | 2.1 |
| *Np(A/C/T)->transit | 22532 | 5121780072 | 4.4e-06 | 4.4 | 0.36 | 2 |
| *ApG->G | 3518 | 992607213 | 3.5e-06 | 3.5 | 0.29 | 2.1 |
| transver | 19746 | 6470241005 | 3.1e-06 | 3.1 | 0.25 | 5 |
| indel+null | 8115 | 6470241005 | 1.3e-06 | 1.3 | 0.1 | NaN |
| double_null | 110 | 6470241005 | 1.7e-08 | 0.017 | 0.0014 | NaN |
| Total | 79215 | 6470241005 | 0.000012 | 12 | 1 | 3.5 |
The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).
Figure 1.
Figure 2. Patients counts and rates file used to generate this plot: STAD-TP.patients.counts_and_rates.txt
The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.
Figure 3. Get High-res Image SNV Mutation rate lego plot for entire set. Each bin is normalized by base coverage for that bin. Colors represent the six SNV types on the upper right. The three-base context for each mutation is labeled in the 4x4 legend on the lower right. The fractional breakdown of SNV counts is shown in the pie chart on the upper left. If this figure is blank, not enough information was provided in the MAF to generate it.
Figure 4. Get High-res Image SNV Mutation rate lego plots for 4 slices of mutation allele fraction (0<=AF<0.1, 0.1<=AF<0.25, 0.25<=AF<0.5, & 0.5<=AF) . The color code and three-base context legends are the same as the previous figure. If this figure is blank, not enough information was provided in the MAF to generate it.
Figure 5. Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.
Column Descriptions:
-
N = number of sequenced bases in this gene across the individual set
-
n = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
n1 = number of nonsilent mutations of type: *CpG->T
-
n2 = number of nonsilent mutations of type: *Np(A/C/T)->transit
-
n3 = number of nonsilent mutations of type: *ApG->G
-
n4 = number of nonsilent mutations of type: transver
-
n5 = number of nonsilent mutations of type: indel+null
-
n6 = number of nonsilent mutations of type: double_null
-
p_cons = p-value for enrichment of mutations at evolutionarily most-conserved sites in gene
-
p_joint = p-value for clustering + conservation
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
Table 3. Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 22. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).
| rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_clust | p_cons | p_joint | p_cv | p | q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TRIM48 | tripartite motif-containing 48 | 135763 | 14 | 14 | 2 | 1 | 0 | 13 | 0 | 1 | 0 | 0 | 0 | 0.94 | 0 | 1 | 0 | 0 |
| 2 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 723978 | 62 | 48 | 31 | 2 | 10 | 40 | 3 | 8 | 1 | 0 | 0.0003 | 0.0051 | 0.000018 | 1.5e-14 | 0 | 0 |
| 3 | PGM5 | phosphoglucomutase 5 | 305048 | 25 | 22 | 7 | 1 | 4 | 18 | 0 | 1 | 2 | 0 | 0 | 1 | 0 | 4.2e-09 | 0 | 0 |
| 4 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 153529 | 25 | 25 | 6 | 0 | 0 | 20 | 0 | 5 | 0 | 0 | 0 | 0.000083 | 0 | 0.000027 | 0 | 0 |
| 5 | CBWD1 | COBW domain containing 1 | 210334 | 30 | 28 | 3 | 0 | 0 | 1 | 0 | 1 | 28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 6 | TP53 | tumor protein p53 | 272497 | 103 | 99 | 66 | 1 | 28 | 21 | 2 | 14 | 37 | 1 | 0 | 0 | 0 | 2.7e-15 | 0 | 0 |
| 7 | ARID1A | AT rich interactive domain 1A (SWI-like) | 1285806 | 46 | 42 | 46 | 2 | 6 | 5 | 1 | 4 | 28 | 2 | 0.42 | 0.46 | 0.65 | 9.7e-15 | 2.1e-13 | 5.4e-10 |
| 8 | SMAD4 | SMAD family member 4 | 374970 | 21 | 19 | 18 | 1 | 5 | 6 | 0 | 6 | 3 | 1 | 6.2e-06 | 0.15 | 0.000014 | 1.6e-08 | 6.7e-12 | 1.5e-08 |
| 9 | RHOA | ras homolog gene family, member A | 132155 | 14 | 13 | 10 | 0 | 1 | 5 | 0 | 8 | 0 | 0 | 4e-07 | 0.55 | 8.6e-06 | 7.5e-08 | 1.9e-11 | 3.7e-08 |
| 10 | MXRA8 | matrix-remodelling associated 8 | 171805 | 13 | 11 | 6 | 2 | 3 | 1 | 0 | 0 | 9 | 0 | 0.01 | 0.6 | 0.028 | 1.7e-09 | 1.2e-09 | 2.1e-06 |
| 11 | IRF2 | interferon regulatory factor 2 | 238325 | 17 | 15 | 16 | 2 | 5 | 2 | 0 | 5 | 4 | 1 | 0.0087 | 0.0016 | 0.00041 | 1.2e-07 | 1.2e-09 | 2.1e-06 |
| 12 | CDH1 | cadherin 1, type 1, E-cadherin (epithelial) | 561265 | 19 | 18 | 18 | 5 | 1 | 6 | 1 | 7 | 4 | 0 | 0.00089 | 0.00038 | 8.8e-06 | 0.000013 | 2.8e-09 | 4.2e-06 |
| 13 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 266766 | 18 | 14 | 16 | 4 | 1 | 4 | 0 | 6 | 7 | 0 | 0.1 | 0.84 | 0.18 | 1.1e-09 | 4.4e-09 | 6.2e-06 |
| 14 | FBXW7 | F-box and WD repeat domain containing 7 | 548512 | 20 | 19 | 13 | 1 | 11 | 4 | 0 | 0 | 5 | 0 | 0.0012 | 0.12 | 0.0018 | 7.9e-06 | 2.7e-07 | 0.00035 |
| 15 | B2M | beta-2-microglobulin | 82186 | 8 | 8 | 8 | 0 | 0 | 2 | 0 | 2 | 3 | 1 | 0.25 | 0.12 | 0.18 | 8.1e-08 | 2.8e-07 | 0.00035 |
| 16 | PTH2 | parathyroid hormone 2 | 47536 | 4 | 4 | 1 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 2e-06 | 0.083 | 0.000028 | 0.011 | 5.1e-06 | 0.0057 |
| 17 | FAM46D | family with sequence similarity 46, member D | 255109 | 6 | 6 | 3 | 0 | 0 | 0 | 0 | 5 | 1 | 0 | 5.6e-06 | 0.097 | 0.000014 | 0.054 | 0.000011 | 0.012 |
| 18 | APC | adenomatous polyposis coli | 1887815 | 35 | 33 | 32 | 5 | 8 | 6 | 1 | 4 | 14 | 2 | 0.13 | 0.95 | 0.18 | 4.8e-06 | 0.000013 | 0.013 |
| 19 | RNF43 | ring finger protein 43 | 479231 | 10 | 9 | 10 | 2 | 2 | 2 | 0 | 0 | 6 | 0 | 0.011 | 0.021 | 0.0088 | 0.00011 | 0.000014 | 0.013 |
| 20 | MAP2K7 | mitogen-activated protein kinase kinase 7 | 219244 | 20 | 14 | 20 | 0 | 10 | 4 | 0 | 3 | 3 | 0 | 0.4 | 0.4 | 0.55 | 6.6e-06 | 0.000049 | 0.044 |
| 21 | WSB2 | WD repeat and SOCS box-containing 2 | 272621 | 7 | 7 | 7 | 1 | 2 | 2 | 0 | 2 | 1 | 0 | 0.11 | 0.17 | 0.16 | 0.000034 | 0.000073 | 0.062 |
| 22 | BCOR | BCL6 co-repressor | 1054518 | 18 | 16 | 18 | 3 | 2 | 4 | 0 | 2 | 10 | 0 | 0.51 | 0.3 | 0.53 | 0.000017 | 0.00012 | 0.095 |
| 23 | TRPS1 | trichorhinophalangeal syndrome I | 862345 | 34 | 30 | 34 | 12 | 6 | 11 | 4 | 8 | 5 | 0 | 0.71 | 0.47 | 0.77 | 0.000016 | 0.00015 | 0.12 |
| 24 | C13orf33 | chromosome 13 open reading frame 33 | 168686 | 6 | 6 | 2 | 1 | 0 | 0 | 0 | 0 | 6 | 0 | 0.0034 | 0.53 | 0.0081 | 0.0015 | 0.00015 | 0.12 |
| 25 | HRCT1 | histidine rich carboxyl terminus 1 | 64764 | 4 | 4 | 1 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 6e-07 | 1 | 0.000012 | 1 | 0.00015 | 0.12 |
| 26 | IAPP | islet amyloid polypeptide | 61356 | 4 | 4 | 3 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0.0009 | 0.97 | 0.0024 | 0.0094 | 0.00027 | 0.19 |
| 27 | XPOT | exportin, tRNA (nuclear export receptor for tRNAs) | 655614 | 9 | 8 | 4 | 19 | 1 | 7 | 0 | 1 | 0 | 0 | 6.6e-06 | 0.96 | 0.000026 | 1 | 0.0003 | 0.2 |
| 28 | MAGEE2 | melanoma antigen family E, 2 | 340871 | 7 | 7 | 5 | 0 | 1 | 1 | 0 | 2 | 3 | 0 | 0.00023 | 0.8 | 0.00059 | 0.053 | 0.00035 | 0.23 |
| 29 | LEMD1 | LEM domain containing 1 | 74907 | 3 | 2 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0.0025 | 0.0054 | 0.00052 | 0.11 | 0.00061 | 0.38 |
| 30 | EDNRB | endothelin receptor type B | 303308 | 20 | 18 | 17 | 4 | 8 | 3 | 0 | 5 | 4 | 0 | 0.043 | 0.84 | 0.12 | 0.00047 | 0.00063 | 0.38 |
| 31 | BCL7C | B-cell CLL/lymphoma 7C | 149528 | 7 | 7 | 7 | 0 | 2 | 2 | 0 | 0 | 3 | 0 | 0.69 | 0.81 | 1 | 0.000066 | 0.0007 | 0.41 |
| 32 | KCNMB2 | potassium large conductance calcium-activated channel, subfamily M, beta member 2 | 159602 | 6 | 6 | 4 | 2 | 0 | 1 | 0 | 5 | 0 | 0 | 0.000099 | 1 | 0.00033 | 0.24 | 0.00084 | 0.47 |
| 33 | LRIT1 | leucine-rich repeat, immunoglobulin-like and transmembrane domains 1 | 347905 | 9 | 9 | 8 | 1 | 2 | 0 | 1 | 3 | 3 | 0 | 0.026 | 1 | 0.058 | 0.0016 | 0.00094 | 0.51 |
| 34 | OR51G1 | olfactory receptor, family 51, subfamily G, member 1 | 213431 | 6 | 6 | 6 | 2 | 2 | 2 | 0 | 2 | 0 | 0 | 0.000095 | 0.78 | 0.00046 | 0.23 | 0.0011 | 0.58 |
| 35 | CBLN3 | cerebellin 3 precursor | 98729 | 4 | 4 | 3 | 2 | 0 | 0 | 0 | 1 | 3 | 0 | 0.34 | 0.11 | 0.29 | 0.00039 | 0.0011 | 0.59 |
Figure S1. This figure depicts the distribution of mutations and mutation types across the TRIM48 significant gene.
Figure S2. This figure depicts the distribution of mutations and mutation types across the PIK3CA significant gene.
Figure S3. This figure depicts the distribution of mutations and mutation types across the PGM5 significant gene.
Figure S4. This figure depicts the distribution of mutations and mutation types across the KRAS significant gene.
Figure S5. This figure depicts the distribution of mutations and mutation types across the CBWD1 significant gene.
Figure S6. This figure depicts the distribution of mutations and mutation types across the TP53 significant gene.
Figure S7. This figure depicts the distribution of mutations and mutation types across the ARID1A significant gene.
Figure S8. This figure depicts the distribution of mutations and mutation types across the SMAD4 significant gene.
Figure S9. This figure depicts the distribution of mutations and mutation types across the RHOA significant gene.
Figure S10. This figure depicts the distribution of mutations and mutation types across the MXRA8 significant gene.
Figure S11. This figure depicts the distribution of mutations and mutation types across the IRF2 significant gene.
Figure S12. This figure depicts the distribution of mutations and mutation types across the CDH1 significant gene.
Figure S13. This figure depicts the distribution of mutations and mutation types across the PTEN significant gene.
Figure S14. This figure depicts the distribution of mutations and mutation types across the FBXW7 significant gene.
Figure S15. This figure depicts the distribution of mutations and mutation types across the B2M significant gene.
Figure S16. This figure depicts the distribution of mutations and mutation types across the FAM46D significant gene.
Figure S17. This figure depicts the distribution of mutations and mutation types across the APC significant gene.
Figure S18. This figure depicts the distribution of mutations and mutation types across the RNF43 significant gene.
Figure S19. This figure depicts the distribution of mutations and mutation types across the MAP2K7 significant gene.
Figure S20. This figure depicts the distribution of mutations and mutation types across the WSB2 significant gene.
Figure S21. This figure depicts the distribution of mutations and mutation types across the BCOR significant gene.
In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.
Table 4. Get Full Table Significantly mutated genes (COSMIC territory only). To access the database please go to: COSMIC. Number of significant genes found: 30. Number of genes displayed: 10
| rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ERBB3 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) | 29 | 6 | 6 | 1326 | 6 | 0 | 0 |
| 2 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 25 | 52 | 24 | 11492 | 166293 | 0 | 0 |
| 3 | TP53 | tumor protein p53 | 103 | 356 | 96 | 78676 | 26850 | 0 | 0 |
| 4 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 62 | 220 | 54 | 48620 | 19016 | 0 | 0 |
| 5 | FBXW7 | F-box and WD repeat domain containing 7 | 20 | 91 | 13 | 20111 | 681 | 0 | 0 |
| 6 | SMAD4 | SMAD family member 4 | 21 | 159 | 17 | 35139 | 66 | 0 | 0 |
| 7 | CDH1 | cadherin 1, type 1, E-cadherin (epithelial) | 19 | 185 | 11 | 40885 | 35 | 6.7e-12 | 4.3e-09 |
| 8 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 18 | 767 | 18 | 169507 | 551 | 1e-11 | 5.8e-09 |
| 9 | APC | adenomatous polyposis coli | 35 | 839 | 18 | 185419 | 374 | 4.6e-11 | 2.3e-08 |
| 10 | ERBB2 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | 12 | 42 | 6 | 9282 | 75 | 2.7e-09 | 1.2e-06 |
Note:
n - number of (nonsilent) mutations in this gene across the individual set.
cos = number of unique mutated sites in this gene in COSMIC
n_cos = overlap between n and cos.
N_cos = number of individuals times cos.
cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.
p = p-value for seeing the observed amount of overlap in this gene)
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
Table 5. Get Full Table A Ranked List of Significantly Mutated Genesets. (Source: MSigDB GSEA Cannonical Pathway Set).Number of significant genesets found: 18. Number of genesets displayed: 10
| rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CHEMICALPATHWAY | DNA damage promotes Bid cleavage, which stimulates mitochondrial cytochrome c release and consequent caspase activation, resulting in apoptosis. | ADPRT, AKT1, APAF1, ATM, BAD, BAX, BCL2, BCL2L1, BID, CASP3, CASP6, CASP7, CASP9, CYCS, EIF2S1, PRKCA, PRKCB1, PTK2, PXN, STAT1, TLN1, TP53 | 20 | AKT1(3), APAF1(5), ATM(30), BAD(3), BAX(1), BCL2(2), BID(2), CASP3(2), CASP6(1), CASP7(2), CASP9(2), EIF2S1(2), PRKCA(3), PTK2(10), PXN(3), STAT1(7), TLN1(14), TP53(103) | 8999666 | 195 | 131 | 156 | 21 | 57 | 46 | 11 | 30 | 48 | 3 | 1.2e-09 | 1.6e-15 | 2.9e-13 |
| 2 | TERTPATHWAY | hTERC, the RNA subunit of telomerase, and hTERT, the catalytic protein subunit, are required for telomerase activity and are overexpressed in many cancers. | HDAC1, MAX, MYC, SP1, SP3, TP53, WT1, ZNF42 | 7 | HDAC1(3), MAX(3), MYC(3), SP1(6), SP3(3), TP53(103), WT1(3) | 2316024 | 124 | 111 | 87 | 11 | 34 | 29 | 2 | 18 | 40 | 1 | 1.6e-08 | 2.4e-15 | 2.9e-13 |
| 3 | ATMPATHWAY | The tumor-suppressing protein kinase ATM responds to radiation-induced DNA damage by blocking cell-cycle progression and activating DNA repair. | ABL1, ATM, BRCA1, CDKN1A, CHEK1, CHEK2, GADD45A, JUN, MAPK8, MDM2, MRE11A, NBS1, NFKB1, NFKBIA, RAD50, RAD51, RBBP8, RELA, TP53, TP73 | 19 | ABL1(4), ATM(30), BRCA1(14), CDKN1A(1), CHEK1(4), CHEK2(7), JUN(3), MAPK8(5), MDM2(3), MRE11A(2), NFKB1(7), NFKBIA(1), RAD50(9), RAD51(1), RBBP8(6), RELA(3), TP53(103), TP73(2) | 9791154 | 205 | 137 | 167 | 22 | 51 | 47 | 8 | 44 | 52 | 3 | 7.8e-09 | 2.6e-15 | 2.9e-13 |
| 4 | P53HYPOXIAPATHWAY | Hypoxia induces p53 accumulation and consequent apoptosis with p53-mediated cell cycle arrest, which is present under conditions of DNA damage. | ABCB1, AKT1, ATM, BAX, CDKN1A, CPB2, CSNK1A1, CSNK1D, FHL2, GADD45A, HIC1, HIF1A, HSPA1A, HSPCA, IGFBP3, MAPK8, MDM2, NFKBIB, NQO1, TP53 | 19 | ABCB1(18), AKT1(3), ATM(30), BAX(1), CDKN1A(1), CPB2(6), CSNK1A1(3), CSNK1D(2), FHL2(2), HIC1(5), HIF1A(5), HSPA1A(1), IGFBP3(5), MAPK8(5), MDM2(3), NFKBIB(5), NQO1(2), TP53(103) | 6815341 | 200 | 134 | 162 | 20 | 56 | 47 | 6 | 33 | 55 | 3 | 1.2e-10 | 2.6e-15 | 2.9e-13 |
| 5 | SA_G1_AND_S_PHASES | Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. | ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 | 15 | ARF1(4), CCND1(1), CDK2(3), CDKN1A(1), CDKN2A(8), CFL1(1), E2F1(2), E2F2(3), MDM2(3), NXT1(2), PRB1(2), TP53(103) | 2761021 | 133 | 114 | 96 | 12 | 38 | 31 | 3 | 16 | 44 | 1 | 6.1e-08 | 3.2e-15 | 2.9e-13 |
| 6 | PMLPATHWAY | Ring-shaped PML nuclear bodies regulate transcription and are required co-activators in p53- and DAXX-mediated apoptosis. | CREBBP, DAXX, HRAS, PAX3, PML, PRAM-1, RARA, RB1, SIRT1, SP100, TNF, TNFRSF1A, TNFRSF1B, TNFRSF6, TNFSF6, TP53, UBL1 | 13 | CREBBP(27), DAXX(9), PAX3(7), PML(7), RARA(2), RB1(6), SIRT1(4), SP100(10), TNF(1), TNFRSF1A(3), TNFRSF1B(2), TP53(103) | 6230239 | 181 | 122 | 143 | 25 | 57 | 43 | 4 | 29 | 47 | 1 | 1.3e-07 | 3.3e-15 | 2.9e-13 |
| 7 | ARFPATHWAY | Cyclin-dependent kinase inhibitor 2A is a tumor suppressor that induces G1 arrest and can activate the p53 pathway, leading to G2/M arrest. | ABL1, CDKN2A, E2F1, MDM2, MYC, PIK3CA, PIK3R1, POLR1A, POLR1B, POLR1C, POLR1D, RAC1, RB1, TBX2, TP53, TWIST1 | 16 | ABL1(4), CDKN2A(8), E2F1(2), MDM2(3), MYC(3), PIK3CA(62), PIK3R1(8), POLR1A(12), POLR1B(4), POLR1C(2), POLR1D(1), RB1(6), TBX2(3), TP53(103), TWIST1(1) | 6653717 | 222 | 147 | 153 | 31 | 56 | 78 | 6 | 31 | 50 | 1 | 3.4e-09 | 3.8e-15 | 2.9e-13 |
| 8 | RBPATHWAY | The ATM protein kinase recognizes DNA damage and blocks cell cycle progression by phosphorylating chk1 and p53, which normally inhibits Rb to allow G1/S transitions. | ATM, CDC2, CDC25A, CDC25B, CDC25C, CDK2, CDK4, CHEK1, MYT1, RB1, TP53, WEE1, YWHAH | 12 | ATM(30), CDC25A(3), CDC25B(4), CDC25C(7), CDK2(3), CHEK1(4), MYT1(14), RB1(6), TP53(103), WEE1(2), YWHAH(3) | 5794957 | 179 | 127 | 139 | 14 | 48 | 41 | 6 | 34 | 47 | 3 | 7e-10 | 3.8e-15 | 2.9e-13 |
| 9 | TIDPATHWAY | On ligand binding, interferon gamma receptors stimulate JAK2 kinase to phosphorylate STAT transcription factors, which promote expression of interferon responsive genes. | DNAJA3, HSPA1A, IFNG, IFNGR1, IFNGR2, IKBKB, JAK2, LIN7A, NFKB1, NFKBIA, RB1, RELA, TIP-1, TNF, TNFRSF1A, TNFRSF1B, TP53, USH1C, WT1 | 18 | DNAJA3(2), HSPA1A(1), IFNG(2), IFNGR1(5), IFNGR2(1), IKBKB(7), JAK2(10), LIN7A(7), NFKB1(7), NFKBIA(1), RB1(6), RELA(3), TNF(1), TNFRSF1A(3), TNFRSF1B(2), TP53(103), USH1C(2), WT1(3) | 5958723 | 166 | 118 | 127 | 26 | 42 | 40 | 3 | 36 | 44 | 1 | 0.000017 | 5e-15 | 3.4e-13 |
| 10 | RNAPATHWAY | dsRNA-activated protein kinase phosphorylates elF2a, which generally inhibits translation, and activates NF-kB to provoke inflammation. | CHUK, DNAJC3, EIF2S1, EIF2S2, MAP3K14, NFKB1, NFKBIA, PRKR, RELA, TP53 | 9 | DNAJC3(3), EIF2S1(2), EIF2S2(3), MAP3K14(3), NFKB1(7), NFKBIA(1), RELA(3), TP53(103) | 3207445 | 125 | 106 | 88 | 7 | 34 | 29 | 2 | 20 | 39 | 1 | 3.6e-09 | 5.7e-15 | 3.5e-13 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.